SYRE icon

Spyre Therapeutics
SYRE

Overview Fund Activity

33 hedge funds and large institutions have $30.4M invested in Spyre Therapeutics in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
33
Holders Change
+10
Holders Change %
+43.48%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
6
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NCM
Nantahala Capital Management
Connecticut
+$6.13M
2
BBA
Baker Bros. Advisors
New York
+$3.65M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$653K
4
BCM
Bridgeway Capital Management
Texas
+$384K
5
PAM
Panagora Asset Management
Massachusetts
+$57K

Top Sellers

1
Jennison Associates
Jennison Associates
New York
-$222K
2
SCM
Sio Capital Management
New York
-$155K
3
Squarepoint
Squarepoint
New York
-$91K
4
PA
Perceptive Advisors
New York
-$43K
5
Renaissance Technologies
Renaissance Technologies
New York
-$42.3K
Name Holding Trade Value Shares
Change 		Shares
Change %
Morgan Stanley
26
Morgan Stanley
New York
$11K +$198 +2 +2%
UBS Group
27
UBS Group
Switzerland
$10K +$6.25K +65 +167%
JPMorgan Chase & Co
28
JPMorgan Chase & Co
New York
$5K +$5K +51 New
Deutsche Bank
29
Deutsche Bank
Germany
$1K -$8.9K -178 -90%
TRCT
30
Tower Research Capital (TRC)
New York
$1K +$1K +9 New
Federated Hermes
31
Federated Hermes
Pennsylvania
$1K +$1K +10 New
Squarepoint
32
Squarepoint
New York
– -$91K -488 Closed
PA
33
Perceptive Advisors
New York
– -$43K -233 Closed
1
2